Wojewodzki Szpital Im. Sw.Ojca Pio W Przemyslu — Clinical Trial Site

72 Registered trials

35 Currently recruiting

Organisation

Wojewodzki Szpital Im. Sw.Ojca Pio W Przemyslu

Location

Peremyshl, Poland

Identifier

ORG-100044073

Address

Ul. Monte Cassino 18, 37-700, Poland

Departments

-
---
5701: Oddzial Onkologiczny z Pododdziałem Dziennej Chemioterapii
5703: Oddział Onkologiczny z Pododdziałem Dziennej Chemioterapii
Cardiology
Cardiology Department
N/A
NA
Oddz.Kardiologii z pododdz. INK, pododdz. Kardiologii Inwazyjnej, pododdz. Kardiochirurgii
Oddzial Kardiologiczny
Oddzial Kardiologii z Pod. Intensywnego Nadzoru Kardiologicznego, Pod. Kardiologii Inwazyjnej
Oddzial Kardiologii z Pododdz Intensywnego Nadzoru Kardiologicznego, Pododdz Kardiologii Inwazyjnej
Oddzial Kardiologii z Pododdzialem Intensywnego Nadzoru Kardiologicznego, Pododdzialem Kardiologii
Oddzial Onkologiczny
Oddzial Onkologiczny z Pododdzialem Dziennej Chemioterapii
Oddzial Onkologiczny z Pododdziałem Dziennej Chemioterapii
Oddzial Onkologiczny z Pododzialem Dziennej Chemioterapii
Oddzial Urologiczny
Oddział Onkologiczny z Pododdziałem Dziennej Chemioterapii
Oddział Kardiologii
Oddział Kardiologii z Pod. Intensywnego Nadzoru Kardiologicznego i Pod. Kardiologii Inwazyjnej
Oddział Kardiologii z Pododdziałem Intensywnego Nadzoru Kardiologicznego i Pododdziałem Kardiologii
Oddział Onkologiczny z Pododdziałem Dziennej Chemioterapii
Oddział onkologiczny z Pododdziałem dziennej chemioterapii
Oddział Urologiczny z Pododdziałem Urologii Onkologicznej
Oncology
Padre Pio Regional Hospital in Przemysl
Surgical department
Wojewodzki Szpital Im. Sw.Ojca Pio W Przemyslu

Clinical trials at this site (72)

Search interface

A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending

2025-523576-23-00 Unresectable Stage III non-small cell lung cancer witho 5
A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Pending

2025-523586-18-00 Non-Small Cell Lung Cancer 5
A Multicenter, Open-Label, Dose Escalation Study of the Safety, Tolerability, and Efficacy of Budiodarone for the Treatment of Subjects with… Pending

2025-523860-19-00 Non-permanent Atrial Fibrillation 10
A Study of YL201 in Combination with Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors Recruiting

2025-523742-27-00 Advanced solid tumors 9 2026-04-28
A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab. Recruiting

2025-521639-34-00 • Non-small cell lung cancer (Stage III, unresectable) 3 2026-04-20
A clinical study of V940 in people with non-small cell lung cancer (V940-013) Recruiting

2025-520902-37-00 Non-small cell lung cancer stage IV 4 2026-04-01
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting

2023-506235-15-00 Limited-Stage Small-Cell Lung Cancer (LS SCLC) 5 2024-11-07
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Pati… Recruiting

2022-502959-54-00 Locally Advanced or Metastatic Non-Small Cell Lung Canc 5 2023-09-26
A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 as monotherapy and in combination with bevacizum… Recruiting

2023-509335-60-00 Advanced solid tumors including (but not limited to), n 1 2023-02-23
A clinical trial of MK-1084, pembrolizumab, and chemotherapy in people with nonsmall cell lung cancer (MK-1084-013) Recruiting

2024-517337-41-00 Completely resected Stage IIA-IIIB (N2) KRAS G12C mutat 5 2026-05-12
HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28
(Title in lay language): A trial to learn how safe AZD0516 is and how well it works with and without other cancer treatments in adults with … Recruiting

2024-520026-11-00 Metastatic Prostate Cancer 7 2026-03-19
Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc… Recruiting

2024-515765-34-00 English First-line extensive-stage small-cell lung canc 5 2026-02-04
Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o… Recruiting

2024-515658-26-00 Unresectable or Metastatic HER2 overexpressing and PD-L 5 2026-01-21
A clinical study of MK-1084 and other treatments for lung cancer (MK-1084-007) Recruiting

2024-514500-14-00 Participants with KRAS G12C-Mutant, Advanced or Metasta 5 2025-12-15
A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-033) Recruiting

2024-517136-21-00 Renal Cell Carcinoma 5 2025-12-05
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatme… Recruiting

2023-508875-35-00 Heart condition 5 2025-09-01
A trial comparing the treatment of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan to the standard treatment in patients with… Recruiting

2024-512583-57-00 HER2-positive locally advanced or metastatic gastric or 5 2025-07-30
A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in iron-deficien… Recruiting

2024-519059-28-00 Chronic Heart Failure 5 2025-07-17
"A research study comparing different doses of CDR132L with placebo on the structure and function of the heart in people with heart failure … Recruiting

2024-515796-35-00 Heart Failure with Preserved Ejection Fraction and Left 4 2025-06-26
A research study comparing CDR132L with placebo on the structure and function of the heart in people with heart failure with reduced/mildly … Recruiting

2024-515797-27-00 Heart Failure with Reduced/Mildly Reducede Ejection Fra 4 2025-06-25
Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Non-small cell lung cancer 10 2025-06-13
A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009) Recruiting

2023-506327-29-00 Non-Small Cell Lung Cancer 5 2025-05-14
A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have ad… Recruiting

2023-505077-32-00 Locally-advanced or metastatic non-squamous non-small c 5 2025-01-28